Li Mingxuan, Bai Jiwei, Wang Shuai, Zhai Yixuan, Zhang Shuheng, Li Chuzhong, Du Jiang, Zhang Yazhuo
Beijing Neurosurgical Institute, Capital Medical University, Beijing, People's Republic of China.
Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China.
Onco Targets Ther. 2020 Aug 20;13:8337-8346. doi: 10.2147/OTT.S257779. eCollection 2020.
Inflammation and malnutrition have been shown to be correlated with tumor progression and a poor prognosis in various cancers. However, the clinical implications of biomarkers of inflammation and malnutrition in chordoma have not been elucidated. We attempted to characterize the fibrinogen and albumin levels in skull base chordoma and investigate their correlations with clinicopathological data and survival.
The preoperative levels of fibrinogen and albumin were assessed in 183 primary skull base chordoma patients. The cutoff values were determined by X-tile software, and their correlations with patient prognosis were further explored using the Kaplan-Meier curve and Cox proportional hazards regression analysis. In addition, the predictive performances of these markers in survival were evaluated by receiver operating characteristic curves.
The values of fibrinogen and albumin in skull base chordoma patients ranged from 1.73 to 7.40 and 37.6 to 53.0 g/L, respectively. The optimal cutoff values for fibrinogen and albumin were 3.29 and 44.60 g/L, respectively. Fibrinogen and albumin were correlated with the patient age and tumor pathology types. Albumin, but not fibrinogen, was associated with the patients' progression-free survival and overall survival. Importantly, the FA score, which combines fibrinogen and albumin, could independently predict both progression-free survival and overall survival, and enhanced the performance of fibrinogen or albumin in survival prediction in skull base chordoma.
Our data reveal the clinical prognostic role of albumin and suggest that the FA score may be a valuable prognostic grading system in skull base chordoma.
炎症和营养不良已被证明与多种癌症的肿瘤进展及预后不良相关。然而，炎症和营养不良生物标志物在脊索瘤中的临床意义尚未阐明。我们试图对颅底脊索瘤中的纤维蛋白原和白蛋白水平进行特征描述，并研究它们与临床病理数据及生存情况的相关性。
对183例原发性颅底脊索瘤患者术前的纤维蛋白原和白蛋白水平进行评估。通过X-tile软件确定临界值，并使用Kaplan-Meier曲线和Cox比例风险回归分析进一步探讨它们与患者预后的相关性。此外，通过受试者工作特征曲线评估这些标志物在生存方面的预测性能。
颅底脊索瘤患者的纤维蛋白原和白蛋白值分别为1.73至7.40以及37.6至53.0 g/L。纤维蛋白原和白蛋白的最佳临界值分别为3.29和44.60 g/L。纤维蛋白原和白蛋白与患者年龄及肿瘤病理类型相关。白蛋白而非纤维蛋白原与患者的无进展生存期和总生存期相关。重要的是，结合纤维蛋白原和白蛋白的FA评分可独立预测无进展生存期和总生存期，并提高了纤维蛋白原或白蛋白在颅底脊索瘤生存预测中的性能。
我们的数据揭示了白蛋白的临床预后作用，并表明FA评分可能是颅底脊索瘤中有价值的预后分级系统。
